Houston, Texas-based ThromboVision, a developer of biomedical diagnostics products based on technology from the Utah Artificial Heart Research Institute, Brigham Young University, and the University of Utah, has raised $400K in the first tranche of a Series A financing. The firm said that the investment will be used to fund the firm's clinical trials, to build its infrastructure, and advanced FDA approval. ThromboVision is developing a system to monitor platelet function. The firm includes founders from the Utah Artificial Heart Research Institute, BYU and the University of Utah.
Top NewsTuesday, December 12, 2006
Utah Technology Spinoff Gets Funds